Alterity Therapeutics Seeks Quotation of ATH Securities in August 2026
TipRanks (Fri, 14-Aug 6:29 AM ET)
Canaccord Genuity Sticks to Their Buy Rating for Alterity Therapeutics (PRNAF)
TipRanks (Thu, 13-Aug 7:35 PM ET)
Alterity Therapeutics Wins Long-Term U.S. Patent Protection for Lead MSA Drug ATH434
TipRanks (Thu, 13-Aug 6:28 AM ET)
TipRanks (Wed, 12-Aug 5:20 PM ET)
Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434
Globe Newswire (Wed, 12-Aug 7:05 AM ET)
Alterity Therapeutics to Present at the 46th Annual Canaccord Genuity Growth Conference
Globe Newswire (Thu, 6-Aug 7:25 AM ET)
Alterity Therapeutics Releases Appendix 4C - Q4 FY26 Quarterly Cash Flow Report & Corporate Update
Globe Newswire (Thu, 30-Jul 7:25 AM ET)
Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026
Globe Newswire (Tue, 21-Jul 7:25 AM ET)
Globe Newswire (Tue, 7-Jul 7:05 AM ET)
Globe Newswire (Tue, 9-Jun 7:05 AM ET)
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
Alterity Therapeutics Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol ATHE.
As of August 14, 2026, ATHE stock price climbed to $4.79 with 6,289 million shares trading.
ATHE has a beta of 2.09, meaning it tends to be more sensitive to market movements. ATHE has a correlation of 0.20 to the broad based SPY ETF.
ATHE has a market cap of $86.82 million. This is considered a Micro Cap stock.
In the last 3 years, ATHE traded as high as $7.00 and as low as $1.00.
ATHE has underperformed the market in the last year with a return of -8.4%, while the SPY ETF gained +21.5%. In the last 3 month period, ATHE fell short of the market, returning +2.6%, while SPY returned +4.0%. However, in the most recent 2 weeks ATHE has outperformed the stock market by returning +8.5%, while SPY returned +3.9%.
ATHE support price is $4.45 and resistance is $4.95 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ATHE shares will trade within this expected range on the day.